BridgeBio Announces CFO Succession
BridgeBio Pharma (Nasdaq: BBIO) announced a leadership transition as Thomas Trimarchi, Ph.D. has been appointed as President and Chief Financial Officer (CFO). Dr. Trimarchi, who recently became Principal Financial Officer, will continue leading the company's FP&A and accounting operations.
The current CFO, Brian Stephenson, Ph.D., is departing for personal reasons and will transition to a consulting role. The company confirmed that Dr. Stephenson's departure is not related to any disagreements regarding company operations, policies, or practices.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato un cambio di leadership con la nomina di Thomas Trimarchi, Ph.D. come Presidente e Direttore Finanziario (CFO). Il Dr. Trimarchi, che è recentemente diventato Direttore Finanziario Principale, continuerà a guidare le operazioni di FP&A e contabilità dell'azienda.
Il CFO attuale, Brian Stephenson, Ph.D., si sta dimettendo per motivi personali e passerà a un ruolo di consulenza. L'azienda ha confermato che le dimissioni del Dr. Stephenson non sono legate a disaccordi riguardanti le operazioni, le politiche o le pratiche aziendali.
BridgeBio Pharma (Nasdaq: BBIO) anunció una transición de liderazgo con la designación de Thomas Trimarchi, Ph.D. como Presidente y Director Financiero (CFO). El Dr. Trimarchi, quien recientemente se convirtió en Director Financiero Principal, continuará liderando las operaciones de FP&A y contabilidad de la empresa.
El CFO actual, Brian Stephenson, Ph.D., se está retirando por razones personales y pasará a un rol de consultoría. La empresa confirmó que la salida del Dr. Stephenson no está relacionada con desacuerdos sobre las operaciones, políticas o prácticas de la empresa.
BridgeBio Pharma (Nasdaq: BBIO)는 Thomas Trimarchi 박사를 사장 겸 최고 재무 책임자(CFO)로 임명하며 리더십 전환을 발표했습니다. Trimarchi 박사는 최근 최고 재무 책임자(Principal Financial Officer)가 되었으며, 회사의 FP&A 및 회계 운영을 계속 이끌 것입니다.
현재 CFO인 Brian Stephenson 박사는 개인적인 이유로 떠나며 컨설팅 역할로 전환할 예정입니다. 회사는 Stephenson 박사의 퇴사가 회사 운영, 정책 또는 관행에 관한 불일치와 관련이 없다고 확인했습니다.
BridgeBio Pharma (Nasdaq: BBIO) a annoncé une transition de leadership avec la nomination de Thomas Trimarchi, Ph.D. en tant que Président et Directeur Financier (CFO). Le Dr Trimarchi, qui est récemment devenu Directeur Financier Principal, continuera à diriger les opérations de FP&A et de comptabilité de l'entreprise.
Le CFO actuel, Brian Stephenson, Ph.D., quitte l'entreprise pour des raisons personnelles et passera à un rôle de consultant. L'entreprise a confirmé que le départ du Dr Stephenson n'est pas lié à des désaccords concernant les opérations, les politiques ou les pratiques de l'entreprise.
BridgeBio Pharma (Nasdaq: BBIO) hat einen Führungswechsel angekündigt, da Thomas Trimarchi, Ph.D. zum Präsidenten und Chief Financial Officer (CFO) ernannt wurde. Dr. Trimarchi, der kürzlich Principal Financial Officer wurde, wird weiterhin die FP&A- und Buchhaltungsoperationen des Unternehmens leiten.
Der derzeitige CFO, Brian Stephenson, Ph.D., verlässt das Unternehmen aus persönlichen Gründen und wird in eine beratende Rolle wechseln. Das Unternehmen bestätigte, dass Dr. Stephensons Ausscheiden nicht mit Meinungsverschiedenheiten über Unternehmensabläufe, -richtlinien oder -praktiken zusammenhängt.
- Smooth leadership transition with internal promotion ensures operational continuity
- Former CFO remains involved as consultant, maintaining institutional knowledge
- Departure of long-standing CFO who helped establish company's financial model
PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Company’s FP&A and accounting operations.
Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s operations, policies or practices. Dr. Stephenson will continue to serve as a consultant to the Company.
“It has been an immense privilege to be a part of the BridgeBio team since its inception and to help serve as many patients as possible through our efforts. I’m proud to have helped pioneer a new type of financial model – one that makes possible broad patient service through the application of portfolio theory and use of formal NPV-driven decision-making frameworks. I look forward to seeing the impact BridgeBio will continue to have on the industry and genetic disease patient communities,” said Dr. Stephenson.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
FAQ
Who is the new CFO of BridgeBio (BBIO) as of March 2025?
Why is Brian Stephenson leaving his position at BridgeBio (BBIO)?
What will be Thomas Trimarchi's responsibilities at BridgeBio (BBIO)?
Will Brian Stephenson maintain any role with BridgeBio (BBIO) after stepping down?
